|
1
|
Cervera R, Khamashta MA, Font J, et al;
The European Working Party on Systemic Lupus Erythematosus.
Systemic lupus erythematosus: clinical and immunologic patterns of
disease expression in a cohort of 1,000 patients. Medicine
(Baltimore). 72:113–124. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mok CC and Tang SS: Incidence and
predictors of renal disease in Chinese patients with systemic lupus
erythematosus. Am J Med. 117:791–795. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Austin HA III, Klippel JH, Balow JE, et
al: Therapy of lupus nephritis. Controlled trial of prednisone and
cytotoxic drugs. N Engl J Med. 314:614–619. 1986.PubMed/NCBI
|
|
4
|
Carette S, Klippel JH, Decker JL, et al:
Controlled studies of oral immunosuppressive drugs in lupus
nephritis. A long-term follow-up. Ann Intern Med. 99:1–8. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boumpas DT, Austin HA III, Vaughn EM, et
al: Controlled trial of pulse methylprednisolone versus two
regimens of pulse cyclophosphamide in severe lupus nephritis.
Lancet. 340:741–745. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mok CC, Wong RW and Lai KN: Treatment of
severe proliferative lupus nephritis: the current state. Ann Rheum
Dis. 62:799–804. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhat P and Radhakrishnan J: B lymphocytes
and lupus nephritis: new insights into pathogenesis and targeted
therapies. Kidney Int. 73:261–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sommerer C, Giese T, Meuer S and Zeier M:
New concepts to individualize calcineurin inhibitor therapy in
renal allograft recipients. Saudi J Kidney Dis Transpl.
21:1030–1037. 2010.PubMed/NCBI
|
|
9
|
Chen W, Tang X, Liu Q, et al: Short-term
outcomes of induction therapy with tacrolimus versus
cyclophosphamide for active lupus nephritis: A multicenter
randomized clinical trial. Am J Kidney Dis. 57:235–244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S, Li X, Qu L, et al: Tacrolimus
versus cyclophosphamide as treatment for diffuse proliferative or
membranous lupus nephritis: a non-randomized prospective cohort
study. Lupus. 21:1025–1035. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Ren H, Zhang Q, et al: Mycophenolate
mofetil or tacrolimus compared with intravenous cyclophosphamide in
the induction treatment for active lupus nephritis. Nephrol Dial
Transplant. 27:1467–1472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Szeto CC, Kwan BC, Lai FM, et al:
Tacrolimus for the treatment of systemic lupus erythematosus with
pure class V nephritis. Rheumatology (Oxford). 47:1678–1681. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zavada J, Pesickova S, Rysava R, et al:
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis:
the Cyclofa-Lune study. Lupus. 19:1281–1289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Austin HA III, Illei GG, Braun MJ and
Balow JE: Randomized, controlled trial of prednisone,
cyclophosphamide, and cyclosporine in lupus membranous nephropathy.
J Am Soc Nephrol. 20:901–911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jadad AR, Moore RA, Carroll D, et al:
Assessing the quality of reports of randomized clinical trials: is
blinding necessary? Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar
|
|
16
|
Moher D, Pham B, Jones A, et al: Does
quality of reports of randomised trials affect estimates of
intervention efficacy reported in meta-analyses? Lancet.
352:609–613. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kjaergard LL, Villumsen J and Gluud C:
Reported methodologic quality and discrepancies between large and
small randomized trials in meta-analyses. Ann Intern Med.
135:982–989. 2001. View Article : Google Scholar
|
|
18
|
Oremus M, Oremus C, Hall GB and McKinnon
MC: Inter-rater and test-retest reliability of quality assessments
by novice student raters using the Jadad and Newcastle-Ottawa
Scales. BMJ Open. 2:e0013682012. View Article : Google Scholar
|
|
19
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyasaka N, Kawai S and Hashimoto H:
Efficacy and safety of tacrolimus for lupus nephritis: a
placebo-controlled double-blind multicenter study. Mod Rheumatol.
19:606–615. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yap DY, Yu X, Chen XM, et al: Pilot 24
month study to compare mycophenolate mofetil and tacrolimus in the
treatment of membranous lupus nephritis with nephrotic syndrome.
Nephrology (Carlton). 17:352–357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT and
Li LS: Successful treatment of class V+IV lupus nephritis with
multitarget therapy. J Am Soc Nephrol. 19:2001–2010. 2008.
|
|
23
|
Valeri A, Radhakrishnan J, Estes D, et al:
Intravenous pulse cyclophosphamide treatment of severe lupus
nephritis: a prospective five-year study. Clin Nephrol. 42:71–78.
1994.PubMed/NCBI
|
|
24
|
Mok CC, Ho CT, Siu YP, et al: Treatment of
diffuse proliferative lupus glomerulonephritis: a comparison of two
cyclophosphamide-containing regimens. Am J Kidney Dis. 38:256–264.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sesso R, Monteiro M, Sato E, Kirsztajn G,
Silva L and Ajzen H: A controlled trial of pulse cyclophosphamide
versus pulse methylprednisolone in severe lupus nephritis. Lupus.
3:107–112. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Belmont HM, Storch M, Buyon J and Abramson
S: New York University/Hospital for Joint Diseases experience with
intravenous cyclophosphamide treatment: efficacy in steroid
unresponsive lupus nephritis. Lupus. 4:104–108. 1995. View Article : Google Scholar
|
|
27
|
Dooley MA and Ginzler EM: Newer
therapeutic approaches for systemic lupus erythematosus:
immunosuppressive agents. Rheum Dis Clin North Am. 32:91–102. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scott LJ, McKeage K, Keam SJ and Plosker
GL: Tacrolimus: a further update of its use in the management of
organ transplantation. Drugs. 63:1247–1297. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee YH, Lee HS, Choi SJ, Dai Ji J and Song
GG: Efficacy and safety of tacrolimus therapy for lupus nephritis:
a systematic review of clinical trials. Lupus. 20:636–640. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng J, Huo D, Wu Q, Yang Z and Liao Y: A
meta-analysis of randomized controlled trials comparing tacrolimus
with intravenous cyclophosphamide in the induction treatment for
lupus nephritis. Tohoku J Exp Med. 227:281–288. 2012. View Article : Google Scholar
|
|
31
|
Midgette AS, Wong JB, Beshansky JR, Porath
A, Fleming C and Pauker SG: Cost-effectiveness of streptokinase for
acute myocardial infarction: A combined meta-analysis and decision
analysis of the effects of infarct location and of likelihood of
infarction. Med Decis Making. 14:108–117. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jones T and Evans D: Conducting a
systematic review. Aust Crit Care. 13:66–71. 2000. View Article : Google Scholar
|
|
33
|
Flather MD, Farkouh ME, Pogue JM and Yusuf
S: Strengths and limitations of meta-analysis: larger studies may
be more reliable. Control Clin Trials. 18:568–579; discussion
661–666. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alarcón GS, Friedman AW, Straaton KV, et
al: Systemic lupus erythematosus in three ethnic groups: III. A
comparison of characteristics early in the natural history of the
LUMINA cohort LUpus in MInority populations: NAture vs Nurture.
Lupus. 8:197–209. 1999.
|
|
35
|
Cooper GS, Parks CG, Treadwell EL, et al:
Differences by race, sex and age in the clinical and immunologic
features of recently diagnosed systemic lupus erythematosus
patients in the southeastern United States. Lupus. 11:161–167.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moroni G, Doria A and Ponticelli C:
Cyclosporine (CsA) in lupus nephritis: assessing the evidence.
Nephrol Dial Transplant. 24:15–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Favre H, Miescher PA, Huang YP, Chatelanat
F and Mihatsch MJ: Ciclosporin in the treatment of lupus nephritis.
Am J Nephrol. 9(Suppl 1): 57–60. 1989. View Article : Google Scholar
|
|
38
|
Chen W, Liu Q, Chen W, et al: Outcomes of
maintenance therapy with tacrolimus versus azathioprine for active
lupus nephritis: a multicenter randomized clinical trial. Lupus.
21:944–952. 2012. View Article : Google Scholar : PubMed/NCBI
|
